Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$63.98 - $85.37 $2,687 - $3,585
-42 Reduced 1.24%
3,352 $245,000
Q3 2022

Nov 03, 2022

BUY
$67.99 - $89.57 $20,261 - $26,691
298 Added 9.63%
3,394 $258,000
Q2 2022

Aug 16, 2022

BUY
$56.6 - $89.9 $4,528 - $7,192
80 Added 2.65%
3,096 $215,000
Q1 2022

May 16, 2022

SELL
$60.15 - $84.52 $46,074 - $64,742
-766 Reduced 20.25%
3,016 $250,000
Q4 2021

Feb 09, 2022

BUY
$75.08 - $121.99 $3,979 - $6,465
53 Added 1.42%
3,782 $284,000
Q3 2021

Nov 12, 2021

BUY
$116.17 - $194.55 $29,042 - $48,637
250 Added 7.19%
3,729 $433,000
Q2 2021

Aug 16, 2021

BUY
$130.4 - $225.58 $241,761 - $418,225
1,854 Added 114.09%
3,479 $772,000
Q1 2021

May 14, 2021

SELL
$124.11 - $190.17 $291,286 - $446,328
-2,347 Reduced 59.09%
1,625 $215,000
Q4 2020

Feb 16, 2021

BUY
$112.16 - $174.14 $445,499 - $691,684
3,972 New
3,972 $687,000
Q2 2020

Aug 13, 2020

SELL
$57.2 - $74.41 $211,754 - $275,465
-3,702 Closed
0 $0
Q1 2020

May 13, 2020

SELL
$57.05 - $95.75 $71,312 - $119,687
-1,250 Reduced 25.24%
3,702 $249,000
Q4 2019

Feb 14, 2020

BUY
$68.3 - $93.8 $20,490 - $28,140
300 Added 6.45%
4,952 $417,000
Q3 2019

Nov 08, 2019

BUY
$61.86 - $97.8 $287,772 - $454,965
4,652 New
4,652 $348,000
Q2 2019

Aug 07, 2019

SELL
$42.22 - $63.23 $709,296 - $1.06 Million
-16,800 Closed
0 $0
Q1 2019

Apr 30, 2019

BUY
$31.96 - $56.12 $536,928 - $942,816
16,800 New
16,800 $809,000
Q4 2018

Feb 12, 2019

SELL
$28.72 - $52.63 $881,704 - $1.62 Million
-30,700 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$32.0 - $52.4 $982,400 - $1.61 Million
30,700 New
30,700 $1.61 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $3.23B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track First Republic Investment Management, Inc. Portfolio

Follow First Republic Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.